Aakash Desai: New Hope in DLL3+ NETs
Jul 31, 2025, 14:34

Aakash Desai: New Hope in DLL3+ NETs

Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on X about a recent article by Martin Wermke et al. published in Journal of Clinical Oncology:

“New hope in DLL3+ NETs

Phase 1 obrixtamig (BI 764532), a DLL3 x CD3 shows encouraging results in pretreated SCLC, epNEC and LCNEC.

  • ORR: 28%
  • LCNEC-L ORR: 70%
  • Median DoR: 8.5 mo
  • CRS: Mostly low-grade and reversible

New player in the DLL3 race!”

Title: Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas

Authors: Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Enriqueta Felip, Miguel Sanmamed, Olatunji Alese, Cyrus Sayehli, Edurne Arriola, Jürgen Wolf, Liza Villaruz, Julia Bertulis, Matus Studeny, Mohamed Bouzaggou, Xiaoyan Fang, Daniel Morgensztern

Read the Full Article on Journal of Clinical Oncology

Aakash Desai: New Hope in DLL3+ NETs

More posts featuring Aakash Desai.